Ocuphire Pharma Investor Updates

P 14 Primary Endpoint: % of Subjects ≥ 15 Letter Gain in Photopic DCNVA at 1 Hour Primary Endpoint Was Met For Nyxol + LDP Gaining ≥ 15 Letters Near Vision In PP Population Percent of Subjetcts (%) 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 15 Letters DCNVA Improvement from Baseline Binocular (PP Population) p=0.003 61% 28% 1 VEGA-1 Phase 2 Trial Time (Hours) Placebo (n=43) Nyxol+LDP (n=43) 33% Placebo Adjusted Responders Percent of Subjects (%) 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects with ≥ 15 Letters DCNVA Improvement from Baseline Binocular (mITT) p=0.003 61% 27% 1 Time (Hours) Placebo (n=44) Nyxol+LDP (n=43) Source: VEGA-1 TLR Table 14.2.1.1 (mITT) and 14.2.1.2 (PP)Percent of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point. 15 letters is 3 lines. 34% Placebo Adjusted Responders, Ocuphire PHARMA

View entire presentation